Disease-Specific HCT Indications and Outcomes Data
New outcomes data and research has defined which patients can benefit from hematopoietic cell transplant (HCT), and when this therapy is best applied. The outcomes data we present here are based on more than 50,000 unrelated donor transplants we facilitated, plus autologous and allogeneic transplant data reported to CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program. This CIBMTR data and analysis are based on more than 330,000 patients from U.S. and global transplant programs.
HCT offers a potential cure for blood cancers such as leukemia, lymphoma, and other life-threatening diseases. View diseases and indications for transplant slide. Access recent research, outcomes, and consultation timing guidelines to support your clinical decisions below.
Leukemia and Myelodysplasia
- Acute Myelogenous Leukemia (AML) - Adult
- Acute Myelogenous Leukemia (AML) - Pediatric
- Acute Lymphoblastic Leukemia (ALL) - Adult
- Acute Lymphoblastic Leukemia (ALL) - Pediatric
- Myelodysplastic Syndromes (MDS)
- Chronic Myelogenous Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)